Bezisterim Phase 2 results highlight potential new treatment approach for Parkinson’s disease symptoms
BioVie's bezisterim shows promising Phase 2 Parkinson's results in patients with elevated inflammation. Explore the findings and Phase 3 outlook.
Pharma & Biotech
Pharma & Biotech
Why BioVie Inc.’s Phase 2 bezisterim data could shift the Parkinson’s disease treatment paradigm
Explore how BioVie Inc.’s bezisterim could reshape Parkinson’s treatment strategies ahead of Phase 2 data. Find out what it means for the industry.